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here are 4 sources of bias in clinical trials: investigator
ias, patient expectation (placebo response), ascertain-
ent bias (inadvertent selection of an unrepresentative
ample), and nonspecific effects such as the normal
axing and waning of symptoms over time and the
uality of the doctor-patient relationship. In drug trials,
hese biases are adequately controlled by comparing
ctive to inert pills, randomly assigning subjects to treat-
ents, blinding both the investigator and subject to
roup assignment, and testing subjects at multiple sites.
owever, there are special problems with conducting
linical trials of behavioral or psychological interventions
hat render these controls inadequate. It is impossible to
lind the experimenter to which treatment is active, it is
ifficult to identify a control treatment that is inactive
ut just as credible to the subject, and doctor-patient
elationship variables are more important than in drug
rials. The inability to blind the experimenter can be
ircumvented by having an independent, blinded inves-
igator assess the outcome, and doctor-patient effects
an be controlled by using multiple, experienced thera-
ists. The most difficult problem, identifying an appro-
riate control treatment, can be solved by adhering to 2
rinciples: the control treatment should be plausible,
nd it should not have a significant impact on the mech-
nism that is thought to explain the effectiveness of the
nvestigational treatment. Investigators should confirm
hat these 2 goals have been achieved by monitoring
xpectation of benefit with a treatment credibility ques-
ionnaire, measuring changes in process variables (vari-
bles that reflect the presumed mechanism of treat-
ent), and monitoring differential dropout rates.
he purpose of a controlled clinical trial is to deter-
mine whether a treatment has specific value that is
ue to a hypothesized mechanism of action and is not
ttributable to nonspecific effects (i.e., sources of bias). A
linical trial differs from usual clinical care. In a clinical
ractice, providers normally take advantage of nonspe-
ific effects such as patient education, a good doctor-
atient relationship, and a positive expectation of benefit
o maximize patient improvement. Moreover, usual clin-
cal practice places less responsibility on patients foreeping symptom records and coming in for checkups.
ecause of these differences, clinical trials seem to un-
erestimate the effectiveness of new treatments relative
o what clinicians expect; therefore, large numbers of
atients need to be studied.
Because controlled clinical trials are so costly, they
hould only be conducted when there is already evidence
rom uncontrolled trials that the treatment is likely to be
ore effective (or at least equally effective and cheaper)
han current therapy, and they should only be initiated
hen the investigators have a clear hypothesis about how
he new treatment works. The importance of having an a
riori hypothesis about the mechanism of action will
ecome apparent.
Do Incontinence Treatment Trials
Require Controls for Placebo
Effects?
Investigators sometimes assume that it is not
ecessary to carry out controlled trials for incontinence
ecause fecal and urinary incontinence are such objective
utcomes that patient expectations (placebo effects) and
nvestigator bias are unlikely to significantly affect the
utcome. From this perspective, enrolling patients who
ave failed to respond to standard medical management
n an uncontrolled trial would appear to be adequate for
easuring outcomes. However, this is clearly not the
ase. Table 11–11 shows that a wide range of behavioral
nterventions have been recommended for the treatment
f incontinence, many of which are highly susceptible to
xpectation effects. As 1 very clear example indicates,
reeman and Baxby11 reported that hypnosis eliminated
rinary incontinence associated with detrusor instability
n 58% of patients and improved another 28%; these
eductions in incontinence were associated with im-
roved cystometrograms in the majority of patients.















































































S160 WILLIAM E. WHITEHEAD GASTROENTEROLOGY Vol. 126, No. 1Nonspecific treatment effects can also confound the
esults of incontinence treatment trials, as shown in a
eport by Heymen et al.10 These investigators enrolled
nly patients who had failed all medical management of
ecal incontinence; instead of placing them immediately
n a behavioral program, they entered all patients in a
-month run-in trial, during which education and good
edical management were instituted. The patients may
lso have received more time and attention from the
nvestigators than they had previously received from
heir family physicians. The result was that 30% of
ubjects resolved their incontinence during the run-in
eriod.10
Types of Bias That Clinical Trials
Seek to Control
Investigator Bias
It is a well-accepted principle that the investiga-
or should not decide which patients are assigned to the
xperimental and control groups because in so doing it
ould be nearly impossible to avoid biasing the study.
o protect against bias, patients are normally assigned to
roups by using a prearranged sequence of random num-
ers. The investigator should not be aware of the next
roup assignment when screening a patient for enroll-
ent because he/she might unconsciously influence
roup assignment through a biased decision regarding
hether the patient meets the inclusion criteria.
Patient Expectation (Placebo Response)
The patient’s confidence level that the treatment
o which he/she has been assigned will be effective can
able 1. Behavioral Treatments for Fecal
and Urinary Incontinence
Intervention Results
iofeedback 50% of patients resolved fecal
incontinence and 25%
improved1,2; biofeedback
superior to drug treatment for
urge urinary incontinence3




egel exercises alone Meta-analysis supports efficacy of




Equal to biofeedback for
constipation8 and fecal
incontinence9
ducation 30% resolved incontinence10;
equivalent to biofeedback9
ypnosis for urge urinary
incontinence
58% symptom free; 28%
improved11rofoundly influence the outcome of the trial. In drug
rials for irritable bowel syndrome (IBS), for example,
lacebo responses of up to 80% have been reported.12
he placebo response is incompletely understood,13 but
ome aspects of it are clear. For example, patients will be
nclined to evaluate their outcomes more positively if
hey believe they are in the active treatment arm, and
hey may be more motivated to comply with homework
ssignments if they believe the treatment will be effec-
ive.
Ascertainment Bias
Self-selection for treatment. If patients are given
choice between an active treatment and placebo, most
f them try to increase their chances of getting the active
reatment. In addition, those assigned to the inactive
reatment arm have less motivation to complete assign-
ents and lower expectation of improvement. In drug
tudies, ascertainment bias can be controlled for by in-
uring that patients are blinded to their treatment as-
ignment, but this is often not feasible with behavioral
nterventions.
Other types of self-selection bias are less obvious and
re more difficult to control by blinding. Through var-
ous forms of publicity, clinics or individual providers
ay become well known for providing specific types of
reatment. The patients who seek out these providers or
ettings may be less motivated, and they may have lower
xpectation of benefit if they are assigned to a different
reatment. Moreover, the patients who seek out special-
zed treatments may be atypical of the total population of
atients with the disorder.
Change in the subject pool over time. Clinical
rials may extend over years. During this time, the types
f patients attending the clinic may change, especially if
here is media publicity about the trial or if new treat-
ents become available. To minimize the impact of
hanges in the subject pool over time, subjects are usu-
lly randomized in relatively small blocks to ensure that
omparable numbers of subjects are assigned to all arms
f the study at each stage of the investigation.
Differential dropout rate. Patients are more likely
o drop out of a trial if their condition is not improving;
he resulting effect is that more people drop out of the
ontrol arms of studies compared with the active treat-
ent arms. Unless the dropouts are retained in the data
nalysis and labeled treatment failures, this differential
ropout rate can seriously bias outcomes. A different
roblem can occur in a behavioral intervention study if
he subjects are not randomized to the treatment group
hey prefer: the subjects may drop out of the study before

















































































January Supplement 2004 CONTROL GROUPS FOR BEHAVIORAL INTERVENTIONS S161atients from the analysis because they were not exposed
o treatment; however, significant numbers of dropouts
ay result in important differences between the treat-
ent and control groups.
Nonspecific Effects
Doctor-patient relationship. In the course of
reating incontinence, physicians provide education and
dvice on exercise and diet. They may also evaluate the
mpact of medications the patient is taking and make
djustments when necessary. These nonspecific aspects of
reatment may be helpful even if they are not regarded as
art of the treatment regimen being evaluated.10 When
atients enter a trial, the physician or research coordina-
or is likely to pay increased attention to these nonspe-
ific factors, which may improve outcomes.
In addition to these nonspecific treatment effects, the
uality of the relationship between the physician and
atient, particularly the physician’s authority and sym-
athetic interest, can influence the outcome of treat-
ent.14 The placebo response is greater in clinical trials
n which the physician meets with the patient at all
ollow-up visits than it is in trials in which a research
oordinator meets with the patients or when the pills are
ailed to the patient.15
Regression to the mean (natural history of the
isease). Chronic disorders such as incontinence tend to
ary in their severity over time. Patients are more likely
o seek treatment, and to be enrolled in clinical trials,
hen their symptoms are more severe, and symptom
everity may decrease simply as a result of the passage of
ime.
Controlling for Bias in Drug Trials
Clinical trials to evaluate the efficacy of new drugs
re carried out frequently and are critically evaluated by
he United States Food and Drug Administration. As a
esult, standards for conducting drug trials have evolved
o deal with most sources of bias. The consensus is that
hese trials should be randomized, double-blinded, par-
llel group, placebo-controlled, multicenter studies.
andomization of patients to treatment by a process in
hich neither the investigator nor the patient has any
oreknowledge of group assignment minimizes the op-
ortunities for investigator bias and self-selection bias.
eeping both the investigator and the patient blinded to
roup assignment throughout the trial minimizes inves-
igator bias, placebo effects, and nonspecific treatment
ffects. Parallel-group designs are preferable to crossover
esigns because they avoid confounding the interpreta-
ion of the data by carry-over effects and minimizenblinding of the study by side effects. Placebo control
roups are used to minimize expectation effects. Recruit-
ng patients from multiple centers or using multiple
herapists from the same center minimizes the possibility
hat nonspecific aspects of the doctor-patient relationship
ill confound the study and makes it easier to accrue
arge samples rapidly.
Special Problems With Designing
Control Groups for Behavioral
Interventions
It Is Not Possible to Blind the Investigator
as to Which Treatment the Patient Is
Assigned and Whether It Is the Active
Treatment or the Control Treatment
To compensate for the increased risk of investi-
ator bias, trials can be designed to (1) use multiple
herapists and have the data analyzed in a way that tests
or differences between therapists and (2) use indepen-
ent, blinded evaluators for assessment of outcome(s).
It Is Difficult to Identify a Control
Intervention That Is Inactive but
Equally Credible
If an inactive but credible control cannot be iden-
ified, it will be difficult to distinguish true treatment
ffects from placebo (expectation) effects. Some ingenious
pproaches to designing placebo controls have been pro-
osed, and these are discussed later. However, the 2 most
ritical steps for insuring the adequate control of placebo
ffects are (1) administering a test (e.g., the Credibility
cale) after the initial exposure to the assigned treatment
hat measures the credibility of the intervention and the
ubject’s level of expectation of positive benefit16 and (2)
sing process measures to assess whether the behavioral
ntervention is changing the physiological or psycholog-
cal response it is supposed to modify, such as a change
n muscle strength or sensory threshold. One should be
ble to show that the hypothesized process is occurring in
he active treatment group and not occurring—or oc-
urring to a lesser degree—in the control group. Ideally,
t should also be possible to correlate changes in the
rocess measure to symptom improvement. A third step
hat can help to preserve the credibility of the treatments
s to pay close attention to how the project is titled,
dvertised, and described in the consent form to mini-
ize cuing patients about which treatment arm is the
ctive one. We have taken the precaution of developing
eparate consent forms for the active and control treat-
ents and have found that institutional review boards for















































































S162 WILLIAM E. WHITEHEAD GASTROENTEROLOGY Vol. 126, No. 1Doctor-Patient Relationship Variables
Are More Important in Behavioral Trials
In behavioral interventions, the goal may be to
hange cognitive attributions, increase perceptual vigi-
ance (awareness of rectal sensation), motivate the patient
o change habits or perform muscle strengthening exer-
ises, or decrease stress-related physiological arousal. The
mount of contact with the therapist, the status of the
herapist, and the quality of the relationship can influ-
nce these outcomes. It is frequently recommended to
nvestigators that they (1) have the same therapists pro-
ide both the active and inactive treatments, (2) use
ultiple therapists, and (3) ensure that the amount of
ontact time is identical for the active and inactive
reatment arms. However, strict adherence to equal con-
act time may reduce the credibility of the control con-
ition by making the therapy situation too artificial. For
xample, if the active treatment is interpersonal therapy
nvolving an initial 3-hour marathon session with the
atient and the control condition is standard medical
are,17 adherence to the equal-time requirement would
e impossible or at least highly artificial. The primary
onsideration is to make the control condition credible to
he patient.
Control Groups for Behavioral
Treatment Trials
Waiting-List (Delayed Start) Control Group
Investigators sometimes randomize their patients
o one group that immediately begins the investigational
reatment and a second group that monitors symptoms
or a period of time equivalent to the time required for
he intervention in the first group before beginning the
reatment. This approach does control for nonspecific
reatment effects such as regression to the mean. How-
ver, this is the worst possible control for placebo effects
ecause no one expects to improve while they are waiting
o begin treatment; this situation creates a negative
xpectation of improvement, which may artificially am-
lify the difference between the active (immediate) and
ontrol (delayed start) groups.
Standard Medical Management
A number of studies have compared behavioral
nterventions for treatment of IBS to standard medical
are.17,18 However, this is also a poor control for placebo
ffects because patients will normally be referred to the
tudy only if they are perceived to have failed standard
edical management. Consequently, being assigned to
more of same treatment” is likely to be associated with
negative expectation for improvement.Pill Placebo
In their initial controlled trial of hypnosis for the
reatment of IBS, Whorwell et al.19 gave a placebo
apsule to control subjects. Placebo capsules may be an
cceptable way of controlling for the patient’s expecta-
ion of improvement, but a few precautions should be
bserved. First, the patient must be provided with a
ationale as to why a drug would work to improve the
ondition. Additionally, to be able to state in the consent
orm that the pills could help, at least a few of the
atients should receive an active drug. A disadvantage of
lacebo pill control groups is that patients who are
ttracted to the trial because they want to try a behav-
oral intervention may be reluctant to take a drug in-
tead.
False Feedback
Biofeedback is a frequently used behavioral inter-
ention for incontinence, and investigators have tried to
esign placebo controls for it. An approach that has been
sed for headache treatment, but not for incontinence, is
o provide visual or auditory feedback that appears to be
ontingent on the patient’s muscle tension, although it is
n fact contingent on the muscle tension of a different
atient. This approach is no longer used because it is too
asy for patients to discover that the feedback display is
nrelated to their own physiological responses; they only
ave to take a deep breath or intentionally tense their
uscle to see if this action changes the feedback dis-
lay.20
Biofeedback Training on a
Different Physiological Response
A good solution to providing a control for
iofeedback training is to train patients to control an
rrelevant physiological response that they believe might
educe their symptoms. For example, in 1 study, patients
ere asked to decrease the alpha frequency band in their
lectroencephalogram21—a response that, on the basis of
edia accounts, they believed would decrease vascular
eadaches but that was, in fact, counterproductive or
rrelevant.
Comparison to Alternative Treatments
That Are Cheaper or Less Effective
Several trials have compared biofeedback training
or incontinence to Kegel exercises22–24 or to verbal
uidance in contracting the pelvic floor muscles.9 If
roperly presented, these alternative treatments may be
s credible to patients as biofeedback. In a landmark



































January Supplement 2004 CONTROL GROUPS FOR BEHAVIORAL INTERVENTIONS S163lanchard25 used a patient support group as the control
ondition because patients found this to be a plausible
reatment for their bowel symptoms despite the fact that
here is no objective evidence that such treatment im-
roves IBS symptoms.
Summary
As the aforementioned examples show, it is pos-
ible to design credible control groups for behavioral
nterventions provided that investigators adhere to 2
rinciples: (1) the control group treatment should be
lausible to patients, and (2) the control group treatment
hould not have a significant impact on the mechanism
hat is thought to explain the effectiveness of the inves-
igational treatment. Investigators should confirm that
hese 2 goals have been achieved by monitoring expec-
ation of benefit, measuring changes in process variables,
nd monitoring differential dropout rates.
References
1. Heymen S, Jones KR, Ringel Y, Scarlett Y, Whitehead WE.
Biofeedback treatment of fecal incontinence: a critical review. Dis
Colon Rectum 2001;44:728–736.
2. Norton C, Kamm MA. Outcome of biofeedback for faecal inconti-
nence. Br J Surg 1999;86:1159–1163.
3. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dom-
browski M, Candib D. Behavioral vs drug treatment for urge
urinary incontinence in older women: a randomized controlled
trial. JAMA 1998;280:1995–2000.
4. Buser WD, Miner PB Jr. Delayed rectal sensation with fecal
incontinence. Successful treatment using anorectal manometry.
Gastroenterology 1986;91:1186–1191.
5. Chiarioni G, Bassotti G, Stanganini S, Vantini I, Whitehead WE,
Stegagnini S. Sensory retraining is key to biofeedback therapy for
formed stool fecal incontinence. Am J Gastroenterol 2002;97:
109–117.
6. Wald A, Tunaguntla AK. Anorectal sensorimotor dysfunction in
fecal incontinence and diabetes mellitus. Modification with
biofeedback therapy. N Engl J Med 1984;310:1282–1287.
7. Berghmans LC, Hendriks HJ, De Bie RA, van Waalwijk van Doorn
ES, Bo K, van Kerrebroeck PE. Conservative treatment of stress
urinary incontinence in women: a systematic review of random-
ized clinical trials. Br J Urol 1998;82:181–191.
8. Koutsomanis D, Lennard-Jones JE, Roy AJ, Kamm MA. Controlled
randomised trial of visual biofeedback versus muscle training
without a visual display for intractable constipation. Gut 1995;
37:95–99.
9. Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm
MA. Randomized controlled trial of biofeedback for fecal inconti-
nence. Gastroenterology 2003;124:1320–1329.0. Heymen S, Jones KR, Ringel Y, Scarlett Y, Drossman DA, White-
head WE. Biofeedback for fecal incontinence and constipation:
the role of medical management and education (abstr). Gastro-
enterology 2001;120(suppl 1):A397.
1. Freeman RM, Baxby K. Hypnotherapy for incontinence caused by
the unstable detrusor. Br Med J (Clin Res Ed) 1982;284:1831–
1834.
2. Whitehead WE, Schuster MM. Irritable bowel syndrome: psycho-
logical and pharmacological treatment. In: Whitehead WE, Schus-
ter MM, ed. Behavioral medicine. Orlando, FL: Academic Press,
1985:211–228.
3. Thompson WG. Placebos: a review of the placebo response. Am J
Gastroenterol 2000;95:1637–1643.
4. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome:
long-term prognosis and the physician-patient interaction. Ann
Intern Med 1995;122:107–112.
5. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syn-
drome: a technical review for practice guideline development.
Gastroenterology 1997;112:2120–2137.
6. Borkovec TD, Nau SD. Credibility of analogue therapy rationales.
J Behav Ther Exp Psychiatry 1972;3:257–260.
7. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of
psychological treatment for the irritable bowel syndrome. Gastro-
enterology 1991;100:450–457.
8. Creed FH, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read
NW, Rigby C, Thompson DG, Tomenson B. The cost-effectiveness
of psychotherapy and SSRI antidepressants for severe irritable
bowel syndrome (abstr). Gastroenterology 2001;120:A115.
9. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy
in the treatment of severe refractory irritable-bowel syndrome.
Lancet 1984;2:1232–1234.
0. Burnette MM, Adams HE. Detection of noncontingent feedback in
EMG biofeedback. Biofeedback Self Regul 1987;12:281–293.
1. Blanchard EB, Peters ML, Hermann C, Turner SM, Buckley TC,
Barton K, Dentinger MP. Direction of temperature control in the
thermal biofeedback treatment of vascular headache. Appl Psy-
chophysiol Biofeedback 1997;22:227–245.
2. Burgio KL, Robinson JC, Engel BT. The role of biofeedback in
Kegel exercise training for stress urinary incontinence. Am J
Obstet Gynecol 1986;154:58–64.
3. Burns PA, Pranikoff K, Nochajski TH, Hadley EC, Levy KJ, Ory MG.
A comparison of effectiveness of biofeedback and pelvic muscle
exercise treatment of stress incontinence in older community-
dwelling women. J Gerontol 1993;48:M167–M174.
4. Shepherd AM, Montgomery E, Anderson RS. Treatment of genu-
ine stress incontinence with a new perineometer. Physiotherapy
1983;69:113.
5. Payne A, Blanchard EB. A controlled comparison of cognitive
therapy and self-help support groups in the treatment of irritable
bowel syndrome. J Consult Clin Psychol 1995;63:779–786.
Address requests for reprints to: William E. Whitehead, Ph.D., Center
or Functional GI and Motility Disorders, Campus Box 7080, University
f North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-
080. e-mail: William_whitehead@med.unc.edu; fax: (919) 966-6842.
Supported by grant RO1 DK57048 from NIDDK.
